Irritable bowel syndrome (IBS), the most common functional gastrointestinal disorder
referred to gastroenterologists, affects 7–10% of the general population worldwide. The lack …

The current developments in metabolomics and metabolic profiling technologies have led to
the discovery of several new metabolic biomarkers. Finding metabolites present in …

Thomas Henry Huxley (1825-1895) once stated,“The great tragedy of science-the slaying of
a beautiful hypothesis by an ugly fact.” Indeed, in drug development not all ground-breaking …

On the basis of our experience in drug and device development, we have identified six
broad categories of issues that profoundly affect the probability for successful translation of …

The US FDA encourages the integration of biomarkers in drug development and their
appropriate use in clinical practice. It is believed that this approach will help alleviate …

The gap of the post-genomic era is increasingly being filled by the metabolomics approach,
comprising a technology for analyzing small molecule endogenous metabolites (≤ 1500 …

There is a growing understanding that aberrant GLIA function is an underlying factor in
psychiatric and neurological disorders. As drug discovery efforts begin to focus on glia …

Proteomics allows characterization of protein structure and function, protein–protein
interactions, and peptide modifications. It has given us insight into the perturbations of …

The first edition of this now classic work helped to establish mass spectrometry as the
premier tool for drug metabolism studies. Completely rewritten from start to finish, Using …

The potential for development of personalised medicine through the characterisation of
novel biomarkers is an exciting prospect for improved patient care. Recent advances in …